Panelists explain that KMT2A-rearranged acute myeloid leukemia (AML) is an aggressive, molecularly distinct leukemia subtype marked by menin-dependent transcriptional dysregulation, poor response to ...

Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

An international panel of pediatric hematologist-oncologists, biologists, geneticists, and laboratory medicine specialists published consensus recommendations for the diagnosis an ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help ...

Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors ...

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...